gineco
ro
infertilitate
hiperandrogenismului ca şi a frecvenţei hiperinsulinemia au fost evocate Concluzii
ovulaţiilor (50% în grupul TZD faţă de ca factori de risc independenţi de Rezistenţa la insulină reprezintă un
12% în grupul placeb­o)
(23)
. Totuşi, din avort spontan. Un studiu­pilot a mecanism fiziopatologic central în SOP.
cauza hepatotoxicităţii, Troglitazon a demonstrat o scădere a numărului Medicamentele ameliorând sensib­ilitatea
fost retras de pe piaţă şi nu există încă de avorturi spontane la femeile cu la insulină şi­au dovedit eficacitatea
studii largi privitoare la Rosiglitazon sau SOP care au urmat un tratament cu atât asupra excesului de androgeni, cât
Pioglitazon. Metformin după concepţie
(25)
. Totuşi, şi asupra prob­lemelor de fertilitate. De
treb­uie sub­liniat că datele privind asemenea, prezintă avantajul ameliorării
Sarcina şi medicamentele siguranţa Metformin în sarcină sunt în egală măsură a profilului metab­olic
ameliorând sensibilitatea
extrem de limitate şi numai câteva al acestor paciente. Datele clinice
la insulină
cazuri raportate au arătat ab­senţa disponib­ile sunt totuşi insuficiente pentru
efectelor teratogene. În privinţa stab­ilirea oportunităţii utilizării lor de
Pe lângă scăderea ratei fertilităţii, TZD, nu există încă studii umane primă intenţie în inducerea ovulaţiei.
femeile cu SOP prezintă un risc asupra folosirii în sarcină, dar studii Treb­uie, de asemenea, ţinut seama de
semnificativ crescut de avort spon­ efectuate pe animale au constat contraindicaţii, cum are fi insuficienţa
tan
(24)
. Rezistenţa la insulină şi defecte de maturare a fetuşilor. renală sau insuficienţa hepatică.
Bibliografie
1. Knochenhauer E.S., Key T.J., Kahsar-Miller M. et al. Prevalence of the 14. Nestler J.E., Jakubowicz d.J. decreases in ovarian cytochrome
polycystic ovary syndrome in unselected black and white women of P450c17 alpha activity and serum free testosterone after reduction
the southeastern United States: A prospective study. J Clin Endocrinol of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;
Metab 1998; 83 : 3.078-82. 335: 617-23.
2. Stein I., Leventhal M. Amenorrhea associated with bilateral polycys- 15. Barbieri R.L., Makris A., Randall R.W. et al. Insulin stimulates an-
tic ovaries. Am J Obstet Gynecol 1935; 29: 181-91. drogen accumulation in incubations of ovarian stroma obtained from
3. Achard C., Thiers J. Le virilisme pilaire et son association à women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62:
l’insuffisance glycolytique (diabète des femmes à barbe). Bull Acad 904-10.
Natl Med 1921; 86: 51-64. 16. Nestler J.E., Jakubowicz d.J., de Vargas A.F. et al. Insulin stimulates
4. Burghen G.A., Givens J.R., Kitabchi A.E. Correlation of hyperandrogen- testosterone biosynthesis by human thecal cells from women with
ism with hyperinsulinism in polycystic ovarian disease. J Clin Endo- polycystic ovary syndrome by activating its own receptor and using
crinol Metab 1980; 50: 113-6. inositolglycan mediators as the signal transduction system. J Clin En-
5. dunaif A., Segal K.R., Futterweit W., dobrjansky A. Profound periph- docrinol Metab 1998; 83: 2.001-5.
eral insulin resistance, independent of obesity, in polycystic ovary 17. Poretsky L., Seto-Young d., Shrestha A. et al. Phosphatidyl-inositol-3
syndrome. diabetes 1989; 38 : 1.165-74. kinase-independent insulin action pathway(s) in the human ovary. J
6. Legro R.S., Kunselman A.R., dodson W.C., dunaif A. Prevalence and Clin Endocrinol Metab 2001; 86: 3.115-9.
predictors of risk for type 2 diabetes mellitus and impaired glucose 18. Gysler M., March C.M., Mishell d.R., Bailey E.J. A decade’s experience
tolerance in polycystic ovary syndrome: A prospective, controlled with an individualized clomiphene treatment regimen including its
study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165- effect on the postcoital test. Fertil Steril 1982; 37: 161-7.
9. 19. Nestler J.E., Jakubowicz d.J., Evans W.S., Pasquali R. Effects of metfor-
7. Kohn A.d., Summers S.A., Birnbaum M.J., Roth R.A. Expression of a min on spontaneous and clomiphene-induced ovulation in the poly-
constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimu- cystic ovary syndrome. N Engl J Med 1998; 338: 1.876-80.
lates glucose uptake and glucose transporter 4 translocation. J Biol 20. Vandermolen d.T., Ratts V.S., Evans W.S. et al. Metformin increases
Chem 1996; 271: 31.372-8. the ovulatory rate and pregnancy rate from clomiphene citrate in
8. Standaert M.L., Galloway L., Karnam P. et al. Protein kinase C-zeta as patients with polycystic ovary syndrome who are resistant to clomi-
a downstream effector of phosphatidylinositol 3-kinase during insu- phene citrate alone. Fertil Steril 2001; 75: 310-5.
lin stimulation in rat adipocytes. Potential role in glucose transport. 21. dunaif A., Scott d., Finegood d., Quintana B., Whitcomb R. The insu-
J Biol Chem 1997; 272: 30.075-82. lin -sensitizing agent troglitazone improves metabolic and reproduc-
9. dunaif A., Segal K.R., Shelley d.R. et al. Evidence for distinctive and tive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol
intrinsic defects in insulin action in polycystic ovary syndrome. dia- Metab 1996; 81: 3.299-306.
betes 1992; 41: 1.257-66. 22. Ehrmann d.A., Schneider d.J., Sobel B.E. et al. Troglitazone improves
10. dunaif A., Xia J., Book C.B., Schenker E., Tang Z. Excessive insulin re- defects in insulin action, insulin secretion, ovarian steroidogenesis,
ceptor serine phosphorylation in cultured fibroblasts and in skeletal and fibrinolysis in women with polycystic ovary syndrome. J Clin En-
muscle. A potential mechanism for insulin resistance in the polycys- docrinol Metab 1997; 82: 2.108-116.
tic ovary syndrome. J Clin Invest 1995; 96: 801-10. 23. Azziz R., Ehrmann d., Legro R.S. et al. Troglitazone improves ovula-
11. dunaif A., Wu X., Lee A., diamanti-Kandarakis E. defects in insu- tion and hirsutism in the polycystic ovary syndrome : A multicenter,
lin receptor signaling in vivo in the polycystic ovary syndrome . Am J double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;
Physiol Endocrinol Metab 2001; 281: E392-E9. 86: 1.626-32.
12. Naz R.K., Thurston d., Santoro N. Circulating tumor necrosis factor 24. Homburg R., Armar N.A., Eshel A., Adams J., Jacobs H.S. Influence of
(TNF)-alpha in normally cycling women and patients with premature serum luteinising hormone concentrations on ovulation, conception,
ovarian failure and polycystic ovaries. Am J Reprod Immunol 1995; and early pregnancy loss in polycystic ovary syndrome. BMJ 1988; 297:
34: 170-5. 1.024-6.
13. Gilling-Smith C., Willis d.S., Beard R.W., Franks S. Hypersecretion 25. Jakubowicz d.J., Iuorno M.J., Jakubowicz S., Roberts K.A., Nestler J.E.
of androstenedione by isolated thecal cells from polycystic ovaries. J Effects of metformin on early pregnancy loss in the polycystic ovary
Clin Endocrinol Metab 1994; 79: 1.158-65. syndrome. J Clin Endocrinol Metab 2002; 87: 524-9.
pag. 110 Vol. 3, Nr. 2 /mai 2007
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68